Skip to main content

Table 4 Repeated measure ANCOVAs of 12-month follow-up measured by GAF and SF-36

From: Psychosocial functioning in patients with treatment-resistant depression after group cognitive behavioral therapy

  Pre-treatment Mean (SD) Post-treatment Mean (SD) 12 months Mean (SD) F value effect size partial Eta 2
ITT (N = 32)      
GAF 60.62(6.36) 66.41(6.74)a 71.22(9.16)b, c 21.44*** 0.32
SF-36 PCS 42.23 (8.88) 48.21 (9.78)a 46.97 (9.34)b 6.71** 0.13
   Physical functioning 76.87(16.84) 84.53 (14.67)a 84.53 (14.11)b 8.28*** 0.15
   Role physical 21.88(39.53) 60.16 (45.73)a 59.38 (40.54)b 11.39*** 0.20
   Bodily pain 65.84(22.56) 70.73 (25.29) 74.06 (24.06) 1.87 0.04
   General health 39.78(14.92) 51.13 (20.59)a 49.91 (19.64)b 5.19** 0.10
SF-36 MCS 26.16 (9.70) 33.59 (11.20)a 38.34 (11.63)b 15.32*** 0.25
   Vitality 26.41(14.66) 40.31 (19.10)a 43.75 (19.76)b 12.59*** 0.22
   Social functioning 44.84(21.91) 60.55 (23.14)a 68.75 (25.79)b 10.51*** 0.19
   Role emotional 13.54(31.52) 37.50 (42.12)a 54.17 (43.79)b 13.07*** 0.22
   Mental health 38.13(16.51) 51.63 (18.16)a 55.83 (18.80)b 13.18*** 0.22
Completers (N = 20)      
GAF 60.24 (6.86) 66.48 (6.40)a 73.81 (7.29)b, c 25.99*** 0.48
SF-36 PCS 43.80 (8.48) 50.32 (7.88)a 48.18 (7.28) 5.10** 0.15
   Physical functioning 80.25(13.13) 89.50 (9.02)a 89.00 (7.88)b 12.31*** 0.31
   Role physical 21.25(40.78) 57.50 (47.37)a 56.25 (38.79)b 5.75** 0.17
   Bodily pain 66.60 (24.30) 73.28 (27.40) 76.30 (26.75) 1.34 0.05
   General health 39.55 (16.17) 55.90 (22.06)a 54.10 (21.19)b 6.94** 0.27
SF-36 MCS 25.23 (9.77) 33.78 (11.06)a 40.56 (10.71)b, c 13.91*** 0.33
   Vitality 25.50 (13.66) 42.25 (16.58)a 47.25 (17.66)b 10.78*** 0.28
   Social functioning 48.00 (21.86) 61.87 (26.12) 73.13 (29.32)b 8.69** 0.24
   Role emotional 13.33 (33.16) 40.00 (45.37) 63.33 (45.76)b, c 11.23*** 0.29
   Mental health 34.80 (16.68) 52.00 (16.57)a 57.60 (17.38)b 15.00** 0.35
  1. *** p < .001, ** p < .01, * p < .05
  2. a: significant difference between Pre- and Post-treatment (p < .05)
  3. b: significant difference between Pre- and 12 months after treatment (p < .05)
  4. c: significant difference between Post- and 12 months after treatment (p < .05)